



under the aegis of
Mumbai Hematology Group

Thursday, 02nd July 2026

Lecture 1: 06.30 pm (IST) onwards
Subject 1: Genomics of DLBCL: Are we ready?



Guest Speaker

Dr. Neeraj Arora

MD (Path), PDF Hematopathology,
PDF Mol Haematology
Director (Mol Biology)
Unipath Specialty Laboratory
Ahmedabad

Lecture 2: 07.30 pm (IST), Polish time : 4.00 pm
Subject 2: Novel Agents in CLL



Guest Speaker

Prof. Wojciech Jurczak

MD, PhD
Consultant and professor of hematology
Memorial Maria Sklodowska
Curie National Research
Institute of Oncology
Cracow, Poland

Panel discussion: 08.30 pm (IST)
Subject 3: Zanubrutinib: Updates in CLL from EHA 2026



Moderator

Dr. M. B. Agarwal, MD

Prof & Head
Dept of Hematology
Bombay Hospital Institute of
Medical Sciences
Mumbai

www.mhgindia.com

Supported by:



Guest Speaker



Dr. Neeraj Arora

MD (Path), PDF Hematopathology,
PDF Mol Haematology
Director (Mol Biology)
Unipath Specialty Laboratory
Ahmedabad

Guest Speaker



Prof. Wojciech Jurczak

MD, PhD
Consultant and professor of hematology
Memorial Maria Skłodowska
Curie National Research
Institute of Oncology
Cracow, Poland

Wojciech Jurczak is a consultant and professor of hematology at Jagiellonian University, Cracow, Poland where he leads the lymphoma team since 1992.

Most of his research activity in the first 15 years was related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation.

At that time radio-immunotherapy with Y90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in monotherapy or as an element of Z-BEAM conditioned ASCT.

During the last decade in Hematology, numerous drugs, with an alternative mechanism of action to classical cytostatics were developed.

Jagiellonian University Lymphoma he leads, participated in over 70 clinical trials, including phase I and phase I followed by expansion cohorts. Wojciech Jurczak is a co-author of publications leading to registration of Ibrutinib, Idelalisib, Belinostat, Lenalidomide, Venetoclax and Rituximab biosimilars.

At present his research is focused on developing II generation BTK inhibitors, antiPD1 molecules, DARTs and BITEs.

He is a member of numerous scientific societies (ASH, ASCO, PLRG, EMCLN and ICOS) and consultant for EMA (European Medicines Agency).

His research papers were published in NEJM, Blood, JCO, The Lancet, Lancet Oncology, Annals of Oncology etc. Cumulative IF > 650, H-index – 20 and citations > 3000.



Dr. M. B. Agarwal, MD

Prof & Head
Dept of Hematology
Bombay Hospital Institute of
Medical Sciences
Mumbai

Bio-sketch

- Prof & Head, Dept of Hematology, Bombay Hospital Institute of Medical Sciences, Mumbai.
- Hon. hematologist: P D Hinduja Hospital, Lilavati Hospital, Breach Candy Hospital, Mumbai.
- Ex-Hon. Prof, Div of hematology, Dept of Medicine, Lokmanya Tilak Municipal Medical College (LTMMC), Sion, Mumbai
- Fellow: College of Hematologists of Sri Lanka (2016-26).
- Counsellor: SOHO (Society of Hematologic Oncology, MD Anderson Cancer Centre, Houston, Texas, USA) - representing India.
- President : Mumbai Haematology Group (2025-26).
- Past president: Indian Society of Haematology (2010-11).
- Advisor: Thalassemia International Federation
- Advisor: Thalassemia Society, Maldives.
- Lifetime Achievement award by Indian Society of Hematology & Blood Transfusion (2025)
- He has received 25 Orations & various Awards from national and international bodies.
- His major contribution in the field of hematology is in the field of education.
- He has published a yearbook in hematology called "Haematology Today" which used to be a multi-author venture containing 60-70 chapters based on recent advances in the field. This book was published every year from 2005 until 2018.
- He has keen interest in clinical research. His original contributions are in the field of multiple myeloma, chronic myeloid leukaemia (CML), iron chelation, antiphospholipid syndrome (APS) & acquired coagulopathies.
- During last 40 years, he has published over 120 original articles in various international and national journals.

Scientific Agenda



Welcome note and introduction of guest speaker
Dr. M. B. Agarwal, Mumbai

Guest lecture

Subject 1: **Genomics of DLBCL: Are we ready?**

Speaker: **Dr. Neeraj Arora, Ahmedabad**

Subject 2: **Novel Agents in CLL**

Speaker: **Prof. Wojciech Jurczak, Poland**

Panel discussion

Subject 3: **Zanubrutinib: Updates in
CLL from EHA 2026**

Moderator: **Dr. M. B. Agarwal, Mumbai**

Panelists
Dr. Anant Gokarn, Mumbai
Dr. Arijit Bishnu, Kolkata
Dr. Asif Iqbal, Guwahati
Dr. Kundan Mishra, Lucknow
Dr. Monisha Harimadhavan
Dr. Revanth Boddu, Bengaluru
Dr. Shailendra Prasad Verma, Lucknow
Dr. Tribikram Panda, Bhubaneswar
Dr. Upendra Sharma, Jaipur

Vote of thanks: Dr. M. B. Agarwal, Mumbai

Registration Link



Click on below link to register:

<https://forms.gle/Uxpp1eDHHH269VKs7>

All registered delegates will receive the attendee joining link on your registered email id. You may also visit our website www.mhgindia.com

Please send your queries related to the webinar on kalpesh@perfectsquare.co.in.



under the aegis of
Mumbai Hematology Group

Hematology Centre, Ghamat Lodge,
804-A, Dr. B. Ambedkar Road,
Dadar TT, Mumbai 400014.
Email ID: mbagarwal1@gmail.com

Supported by:



Event Partner:

